Daewoong Pharma's Nabota (daxibotulinumtoxinA) has crossed 1 trillion won (~$750M USD) in annual sales, driven by strong domestic Korean demand and an accelerating global push. Nabota is a neuromodulator with a longer duration of action than Botox (up to 6 months vs. 3–4 months), positioning it as a differentiated alternative in markets where payers or patients value extended intervals between treatments.
Market
Daewoong's Nabota Hits 1 Trillion Won in Sales — Korean Toxin Maker Accelerates U.S. and Global Expansion
A third-party neuromodulator gains traction as price competition reshapes the toxin market.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
A longer-acting neuromodulator at parity pricing could shift patient preference and compress toxin margins.
For U.S. medspas, Nabota's momentum abroad signals that third-party neuromodulator adoption is maturing. While Nabota has FDA approval and is marketed in the U.S., it remains a niche player relative to Allergan and Galderma. However, as Daewoong scales manufacturing and distribution, pricing pressure on Botox and Dysport will intensify. Practices in competitive markets should monitor Nabota's rebate offers; a longer-acting toxin at parity or lower per-unit cost could shift patient preference, especially for high-volume injectors. The 1 trillion won milestone suggests Daewoong is investing in market expansion—expect more aggressive U.S. sampling, rebate programs, and DSO partnerships within 12–24 months.
Source: original report ↗
Frequently asked questions
How long does Nabota last compared to Botox?
Nabota lasts up to 6 months, compared to Botox's typical 3–4 month duration. This extended interval between treatments is Nabota's key differentiator and appeals to patients seeking longer-lasting results with fewer injection appointments.
Is Nabota FDA approved in the United States?
Yes, Nabota (daxibotulinumtoxinA) has FDA approval and is currently marketed in the U.S., though it remains a niche player behind Allergan and Galderma's established neuromodulators.
What does Nabota's 1 trillion won sales milestone mean for U.S. medspas?
Nabota's $750M annual sales milestone indicates Daewoong is scaling aggressively and will likely increase U.S. market penetration through rebate programs, sampling, and DSO partnerships within 12–24 months. This will intensify price competition on Botox and Dysport, particularly in competitive markets.
Should medspas stock Nabota as a third-party neuromodulator option?
Medspas in price-sensitive or competitive markets should monitor Nabota's rebate offers and per-unit pricing. If Nabota achieves parity or lower cost with its 6-month duration, it could shift patient preference, especially among high-volume injectors seeking to reduce treatment frequency.
What is driving Nabota's global expansion?
Strong domestic Korean demand combined with Daewoong's manufacturing scale-up is fueling international growth. The company's 1 trillion won sales milestone is being reinvested in market expansion, signaling aggressive U.S. and global distribution strategies ahead.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.